LQDA

Liquidia Corporation

September 30, 2026 · intraday

Rarity

11.63

Peak move

−57.35%

Float cap

$5.0B

Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases such as pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. It commercializes YUTREPIA, an inhaled dry powder treprostinil, in the United States and shares profit from Sandoz's generic treprostinil injection. It also develops L606 and calls on U.S. healthcare providers involved in treatment, distribution, and reimbursement.

• patent_eventSep 30 · 13:20 ET

  The U.S. District Court for the District of Delaware found claims 1 and 14 of United Therapeutics' '327 patent, covering treatment of PH-ILD with inhaled treprostinil, valid and infringed by Liquidia's YUTREPIA, while the remaining asserted claims were invalid; the parties must submit a proposed form of judgment within one week.

  wireglobenewswire.comwireglobenewswire.comSEC8-K 0001104659-26-112420Webliquidia.comWebtmcnet.comWebbenzinga.comWebsec.govWebs4.biz.itc.cn
• analyst_ratingSep 24 · 07:00 ET

  Zacks Research downgraded Liquidia (LQDA) to "Strong Sell" from "Hold" in a research note, citing competitive risk to its YUTREPIA pulmonary hypertension franchise; Zacks' consensus 2026 EPS estimate had been cut to $2.57 from $3.02.

  Webmarketbeat.com